ClinicalTrials.gg

Program

Mesenchymal Stem Cell

Also written as “Mesenchymal stem cell”, “mesenchymal stem cell” and “Mesenchymal Stem Cell Injection”.

Its studies are mostly in COVID-19 · Osteoarthritis, Knee · Myocardial Ischemia · Osteoarthritis · Acquired Immunodeficiency Syndrome, led by 8 companies.

Furthest: phase 2, since Aug 3, 201711 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rohto Pharmaceutical41 open or runningphase 2since Aug 3, 2017Aug 3, 2017Sep 30, 2028phase 2 · NCT07192211
Azidus Brasil10 open or runningphase 2since Mar 18, 2020Mar 18, 2020none ahead
CAR-T (Shanghai) Biotechnology10 open or runningearly phase 1since Oct 11, 2019Oct 11, 2019none ahead
Cell Energy Life Sciences Group11 open or runningphase 2since May 15, 2023May 15, 2023Jul 10, 2027phase 2 · NCT05939167
Meluha Life Sciences SDN BHD10 open or runningphase 2since Aug 17, 2020Aug 17, 2020none ahead
Pharmicell10 open or runningphase 1since Jan 13, 2015Jan 13, 2015none ahead
Tianjin Weikai Bioeng.10 open or runningphase 2since Feb 18, 2019Feb 18, 2019none ahead
TricelX11 open or runningphase 2since Mar 17, 2026Mar 17, 2026May 2027phase 2 · NCT07487766

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2015First study: phase 1 study in Erectile DysfunctionNew to PharmicellPharmicell · NCT02344849 · 10 enrolled · Korea, Republic of
  2. Aug 3, 2017Rohto Pharmaceutical's first study: phase 2 study in Decompensated Liver CirrhosisNew to Rohto PharmaceuticalRohto Pharmaceutical · NCT03254758 · 21 enrolled · Japan
  3. Feb 18, 2019Tianjin Weikai Bioeng.'s first study: phase 2 study in Acute-On-Chronic Liver FailureNew to Tianjin Weikai Bioeng.Tianjin Weikai Bioeng. · NCT03863002 · 45 enrolled · China
  4. Oct 11, 2019CAR-T (Shanghai) Biotechnology's first study: early phase 1 study in Osteoarthritis, KneeNew to CAR-T (Shanghai) BiotechnologyCAR-T (Shanghai) Biotechnology · NCT04130100 · 60 enrolled · China
  5. Mar 18, 2020Azidus Brasil's first study: phase 2 study in COVID-19 PneumoniaNew to Azidus BrasilAzidus Brasil · NCT04315987 · 90 enrolled · Brazil
  6. Aug 17, 2020Meluha Life Sciences SDN BHD's first study: phase 2 study in Osteoarthritis, KneeNew to Meluha Life Sciences SDN BHDMeluha Life Sciences SDN BHD · NCT04520945 · 100 enrolled · Malaysia
  7. Aug 20, 2020Phase 1 study in Severe Acute Respiratory Syndrome Coronavirus 2Rohto Pharmaceutical · NCT04522986 · 6 enrolled · Japan
  8. May 9, 2021Phase 2 study in SARS-CoV-2 Infection( COVID-19 )Rohto Pharmaceutical · NCT04888949 · 15 enrolled · Japan
  9. May 15, 2023Cell Energy Life Sciences Group's first study: phase 2 study in Acquired Immunodeficiency SyndromeNew to Cell Energy Life Sciences GroupCell Energy Life Sciences Group · NCT05939167 · 150 planned · China
  10. Aug 28, 2025Phase 2 study in Myocardial IschemiaRohto Pharmaceutical · NCT07192211 · 50 planned · Japan
  11. Mar 17, 2026TricelX's first study: phase 2 study in OsteoarthritisNew to TricelXTricelX · NCT07487766 · 75 planned · United States

Ahead

  1. May 2027Primary completion: phase 2 study in OsteoarthritisTricelX · NCT07487766
  2. Jul 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeCell Energy Life Sciences Group · NCT05939167
  3. Sep 30, 2028Primary completion: phase 2 study in Myocardial IschemiaRohto Pharmaceutical · NCT07192211

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07487766Osteoarthritis · United States2Not yet recruitingTricelXMay 202775
NCT07192211Myocardial Ischemia · Japan2RecruitingRohto PharmaceuticalSep 30, 202850
NCT05939167Acquired Immunodeficiency Syndrome · China2RecruitingCell Energy Life Sciences GroupJul 10, 2027150
NCT04888949SARS-CoV-2 Infection( COVID-19 ) · Japan2CompletedRohto PharmaceuticalMay 18, 202315
NCT04522986Severe Acute Respiratory Syndrome Coronavirus 2 · Japan1CompletedRohto PharmaceuticalFeb 2, 20216
NCT04520945Osteoarthritis, Knee · Malaysia2UNKNOWNMeluha Life Sciences SDN BHDSep 30, 2021100
NCT04315987COVID-19 Pneumonia · Brazil2CompletedAzidus BrasilFeb 28, 202190
NCT04130100Osteoarthritis, Knee · ChinaEarly 1UNKNOWNCAR-T (Shanghai) BiotechnologySep 30, 202160
NCT03863002Acute-On-Chronic Liver Failure · China2UNKNOWNTianjin Weikai Bioeng.Oct 1, 202145
NCT03254758Decompensated Liver Cirrhosis · Japan2CompletedRohto PharmaceuticalApr 13, 202321
NCT02344849Erectile Dysfunction · Korea, Republic of1CompletedPharmicellJan 31, 201810

How it is read

Names in the registry

  • “Mesenchymal stem cell”, 4 entries
  • “mesenchymal stem cell”, 2 entries
  • “Mesenchymal Stem Cell Injection”, 1 entry
  • “NestaCell®”, 1 entry
  • “Chondrogen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Mesenchymal Stem Cell (Rohto Pharmaceutical): development program | ClinicalTrials.gg